Wednesday, July 8, 2026

Drug profile · INN

remifentanil hydrochloride

remifentanil hydrochloride (REMIFENTANIL HYDROCHLORIDE) is a mu opioid receptor agonist. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 2
News articles 0
Drug details — remifentanil hydrochloride
US status
approved
Class
Route
INJECTION
Patents
20
Programs
2
Data quality
0.84

Quick answer

remifentanil hydrochloride (REMIFENTANIL HYDROCHLORIDE) is a mu opioid receptor agonist. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN remifentanil hydrochloride
Brand REMIFENTANIL HYDROCHLORIDE
Mechanism Mu opioid receptor agonist
Target Mu-type opioid receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Mu opioid receptor agonist

Primary target: Mu-type opioid receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Remifentanil Phase 3 · Chinese Academy of · Analgesia
  2. Multivalent recombinant OspA Lyme Borreliosis Vaccine Phase 2 · Takeda · Prophylaxis of Lyme Borreliosis

Related & competitor drugs

  1. alvimopan Mu opioid receptor antagonist
  2. loperamide hydrochloride Mu opioid receptor agonist
  3. methadone hydrochloride Mu opioid receptor agonist
  4. morphine sulfate Mu opioid receptor agonist
  5. oxycodone Mu opioid receptor agonist
  6. oxycodone hydrochloride Mu opioid receptor agonist

Related patents

  1. US 2025129145

    BI- AND MULTIVALENT ALBUMIN BINDERS

    Expires Wed Apr 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12269155

    Multivalent vaccines for rabies virus and coronaviruses

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12227584

    Multivalent and multispecific OX40-binding fusion proteins

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 12187804

    Multivalent and multispecific 41BB-binding proteins

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11976126

    Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11938221

    Multivalent nanoparticle-based vaccines

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11235054

    Multivalent vaccine composition

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11191727

    Multivalent nanoparticle-based vaccines

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11117973

    Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11117972

    Multivalent and multispecific OX40-binding fusion proteins

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 11041170

    Multivalent vaccines for rabies virus and coronaviruses

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 10849975

    Multivalent vaccines for rabies virus and filoviruses

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 10844129

    Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 10738275

    Paenibacillus sp. strain, cultivation method and use of the same

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 10610492

    Spray dry method for encapsulation of biological moieties and chemicals in polymers cross-linked by multivalent ions for controlled release applications

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 10501551

    Multivalent and multispecific 41BB-binding fusion proteins

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 10472412

    Bispecific multivalent fusion proteins

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 10420811

    Cultivation of selenium-rich Cyclocarya paliurus plant, extraction and use of active ingredients thereof

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 10308720

    Multivalent and multispecific DR5-binding fusion proteins

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 10113145

    Paenibacillus sp. strain, cultivation method and use of the same

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is remifentanil hydrochloride?

remifentanil hydrochloride (REMIFENTANIL HYDROCHLORIDE) is a mu opioid receptor agonist. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for remifentanil hydrochloride?

REMIFENTANIL HYDROCHLORIDE is a marketed brand name for remifentanil hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of remifentanil hydrochloride?

remifentanil hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.